• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
180845 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  : W+ d# u7 U0 u3 T/ \- j! [
$ h6 q: s1 F5 u5 M7 W' k

1 S3 [* @  z! b3 K; ^Sub-category:: Q% V  b6 T2 _8 ]4 x6 \9 }6 g3 s
Molecular Targets 4 C5 a' y; i! }" u

" O% {, ^& Y4 U# i0 q( n7 ?6 ~, V7 \
- l" ~" e" ^! Q5 X0 `2 q9 ZCategory:: O9 v/ {( x! z5 R' L6 [: X  l
Tumor Biology
& P+ k: \  m$ r4 j1 ^, J" R( w3 F7 s" @7 B

4 w2 O2 w1 [! r" O2 U) x, tMeeting:
" s; b# N& {0 {3 W" E2011 ASCO Annual Meeting 2 n6 k  ~% @) n, h) ?: q

- B* D5 l5 s! V$ _, U3 R' p9 r2 j
# w, n" {5 Y, [Session Type and Session Title:, X/ O# S; N" E8 H
Poster Discussion Session, Tumor Biology
6 `( F3 n! p* O+ v! t
6 c7 C1 K- C6 K! h6 Z9 Z- o3 X4 p
$ J9 z4 H8 _; {8 Y) w' nAbstract No:
- o$ o( T. y/ h( y1 V: {: U% x' h- |10517
1 `- W/ G4 X: V9 T; u
8 L4 w8 s0 V8 b3 `
  i5 j( \5 j1 o9 _6 iCitation:% r; ?* s* U# y! o. m* h
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 E2 F9 c1 d' W- m" L6 o# P2 L
0 j& E2 T$ S4 H: p# ]2 q
# z( O5 A) T, O- }6 q
Author(s):
* S/ `% ?# U" J% E/ PJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) V& E, t, ~( H5 k; H$ |' O4 _7 p
! K, _* ^8 C2 j  E
" |' Y5 a4 |' h3 |. U

/ M4 `' x; G1 I9 h3 |Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings., k7 v4 L8 S$ k0 ?/ f

' z* T% p3 u# T5 J4 T; m8 XAbstract Disclosures& ]8 R! M* {  O9 B- {2 q
5 F9 t8 p8 C( @0 I
Abstract:9 j0 `( o/ M. w! D4 r6 D+ l
0 E' _- p) r& T: H

, m/ m9 \' s- l" MBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.* m) g" X# F6 q8 R0 |7 r) T
9 H; \: Y' n" s' ?0 {; X' G7 `
# p. p# Y; p) p
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
, O8 A$ d' d0 H, _0 ?+ T+ e* I. v* ?没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

* f5 p: O! S' a/ s5 f5 t化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
* w) H1 D' a; \4 ?易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
, p) ?! y$ Q5 F8 ]& RALK一个指标医院要900多 ...

3 v: ]7 K4 R- m* s2 @) J3 i; i平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
  l- l/ t8 P( t& n' [
+ B, P& A, z$ a% y# c现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表